Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.69 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.56 |
| ▸ | SCD5 | Q86SK9 | 5/20 | 0.55 |
| ▸ | SCD | O00767 | 3/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.55 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.55 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.55 |
| ▸ | CCNC | P24863 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | PPID | Q08752 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1853141 | 1.00 | RIPK1 (0.69) | RIPK1HSP90AA1HSP90AB1EPHX2HSD11B1 | |
| SCHEMBL1847627 | 1.00 | RIPK1 (0.69) | RIPK1HSP90AA1HSP90AB1EPHX2HSD11B1 | |
| SCHEMBL216202 | 0.95 | RIPK1 (0.62) | RIPK1HSP90AA1HSP90AB1EPHX2HSD11B1 | |
| SCHEMBL27574946 | 0.95 | RIPK1 (0.62) | RIPK1HSP90AA1HSP90AB1EPHX2HSD11B1 | |
| SCHEMBL27574934 | 0.95 | RIPK1 (0.62) | RIPK1HSP90AA1HSP90AB1EPHX2HSD11B1 | |
| Water SCHEMBL27700791 | 0.93 | RIPK1 (0.60) | RIPK1HSP90AA1HSP90AB1EPHX2HSD11B1 | |
| SCHEMBL311128 | 0.90 | RIPK1 (0.57) | RIPK1HSP90AA1HSP90AB1EPHX2HSD11B1 | |
| SCHEMBL17026995 | 0.89 | RIPK1 (0.67) | RIPK1HSP90AA1HSP90AB1EPHX2HSD11B1 | |
| SCHEMBL3062584 | 0.87 | RIPK1 (0.67) | RIPK1HSP90AA1HSP90AB1EPHX2HSD11B1 | |
| SCHEMBL27659813 | 0.86 | RIPK1 (0.57) | RIPK1HSP90AA1HSP90AB1EPHX2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828369-B2 | Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 | MERCK SHARPE & DOHME CORP. (US) | 2017-11-28 | — | — | US | claimed |
| US-20170275274-A1 | ISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | US | claimed |
| EP-3188731-A1 | ISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | Merck Sharp & Dohme Corp. (US) | 2017-07-12 | — | — | EP | claimed |
| WO-2016036638-A1 | ISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | MERCK SHARP & DOHME CORP. (US) | 2016-03-10 | — | — | WO | claimed |
| EP-4612156-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024097296-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-4305021-A1 | USP30 INHIBITORS AND USES THEREOF | Vincere Biosciences, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022192562-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| CN-112010861-A | PDE9 inhibitors having an imidazotriazinone backbone and an imidazopyrazinone backbone for the treatment of peripheral diseases | H.隆德贝克有限公司 | 2020-12-01 | — | — | CN | disclosed |
| CN-107810187-B | PDE9 inhibitors having an imidazotriazinone backbone and an imidazopyrazinone backbone for the treatment of peripheral diseases | H.隆德贝克有限公司 | 2020-09-15 | — | — | CN | disclosed |
| EP-3538522-A1 | ROR GAMMA MODULATORS | Bristol-Myers Squibb Company (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-3355890-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| WO-2018089406-A1 | ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275274-A1 | ISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | DGAT2, DGAT1, MOGAT2 | RIPK1 3151/4885HSP90AA1 2660/4885HSP90AB1 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.